Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) EBITDA (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed EBITDA for 12 consecutive years, with -$14.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA fell 344.95% year-over-year to -$14.2 million, compared with a TTM value of $28.1 million through Sep 2025, up 101.55%, and an annual FY2024 reading of $31.8 million, up 6670.45% over the prior year.
  • EBITDA was -$14.2 million for Q3 2025 at CytomX Therapeutics, down from -$120000.0 in the prior quarter.
  • Across five years, EBITDA topped out at $23.5 million in Q1 2025 and bottomed at -$35.1 million in Q4 2021.
  • Average EBITDA over 5 years is -$8.0 million, with a median of -$6.5 million recorded in 2024.
  • Peak annual rise in EBITDA hit 1795.78% in 2024, while the deepest fall reached 505.57% in 2024.
  • Year by year, EBITDA stood at -$35.1 million in 2021, then skyrocketed by 77.3% to -$8.0 million in 2022, then skyrocketed by 112.48% to $995000.0 in 2023, then soared by 1795.78% to $18.9 million in 2024, then crashed by 175.06% to -$14.2 million in 2025.
  • Business Quant data shows EBITDA for CTMX at -$14.2 million in Q3 2025, -$120000.0 in Q2 2025, and $23.5 million in Q1 2025.